# Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

> **NCT00445887** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 60 (actual)

## Conditions studied

- Ovarian Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Levonorgestrel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00445887
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-10
- **Primary completion:** 2013-12-11
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445887, "Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00445887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*